[go: up one dir, main page]

BR9905788A - Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados - Google Patents

Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados

Info

Publication number
BR9905788A
BR9905788A BR9905788-3A BR9905788A BR9905788A BR 9905788 A BR9905788 A BR 9905788A BR 9905788 A BR9905788 A BR 9905788A BR 9905788 A BR9905788 A BR 9905788A
Authority
BR
Brazil
Prior art keywords
derivatives
methods
cell growth
abnormal cell
imidazolidin
Prior art date
Application number
BR9905788-3A
Other languages
English (en)
Inventor
Joseph Peter Lyssikatos
Bingwei Vera Yang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9905788A publication Critical patent/BR9905788A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Patente de Invenção: <B>"DERIVADOS DE 2-(2-OXO-ETILIDENO)-IMIDAZOLIDIN-4-ONA E COMPOSIçõES E MéTODOS PARA A INIBIçãO DO CRESCIMENTO DE CéLULA ANORMAL QUE COMPREENDEM OS REFERIDOS DERIVADOS"<D>. A presente invenção refere-se a compostos da fórmula em que R~ 1~, R~ 2~, R~ 3~ e R~ 4~ são conforme aqui definidos. A invenção também refere-se a composições farmacêuticas que contêm os compostos de Fórmula I e a métodos de inibição do crescimento da célula anormal, incluindo câncer, num mamífero pela administração de compostos de Fórmula I ao referido mamífero.
BR9905788-3A 1998-12-02 1999-12-02 Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados BR9905788A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11060798P 1998-12-02 1998-12-02

Publications (1)

Publication Number Publication Date
BR9905788A true BR9905788A (pt) 2000-08-29

Family

ID=22333953

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9905788-3A BR9905788A (pt) 1998-12-02 1999-12-02 Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados

Country Status (5)

Country Link
US (1) US6194438B1 (pt)
EP (1) EP1006113A1 (pt)
JP (1) JP2000186075A (pt)
BR (1) BR9905788A (pt)
CA (1) CA2291880A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200300473A1 (ru) * 2000-10-16 2003-08-28 Неофарм, Инк. Терапевтическая композиция на основе митоксантрона (варианты) и липидный препарат, способ его получения и способ лечения заболевания млекопитающего с его использованием
RS20050430A (sr) * 2002-12-19 2007-08-03 Pfizer Inc., Jedinjenja 2-(1h-indazol-6-ilamino)- benzamida kao inhibitori protein kinaza, korisni u tretmanu oftalmoloških bolesti
WO2005051392A1 (en) 2003-11-20 2005-06-09 Children's Hospital Medical Center Gtpase inhibitors and methods of use
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
JP2008510792A (ja) * 2004-08-26 2008-04-10 ファイザー・インク タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物
PT1786785E (pt) * 2004-08-26 2010-05-21 Pfizer Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
EP1784396B8 (en) * 2004-08-26 2011-04-20 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
JP2009504773A (ja) * 2005-08-19 2009-02-05 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−二環式スルホンアミド阻害剤
SI1933871T1 (sl) 2005-09-07 2013-10-30 Amgen Fremont Inc. Humana monoklonska protitelesa proti aktivin receptorju podobni kinazi-1
DK1926996T3 (da) 2005-09-20 2012-01-23 Osi Pharmaceuticals Llc Biologiske markører, som er prædiktive for anti-cancer-reaktion på insulinlignende vækstfaktor-1-receptorkinasehæmmere
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
WO2008010061A2 (en) * 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
SI2056874T1 (sl) 2006-08-21 2012-12-31 F. Hoffmann-La Roche Ag Terapija tumorjev s protitelesom proti vegf
JP2010524940A (ja) * 2007-04-20 2010-07-22 シェーリング コーポレイション ピリミジノン誘導体およびそれらの使用方法
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
WO2013166043A1 (en) 2012-05-02 2013-11-07 Children's Hospital Medical Center Rejuvenation of precursor cells
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
EP4013402B1 (en) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42 inhibitors for use in the treatment of age-related depression, sarcopenia or frailty
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2022206742A1 (zh) * 2021-03-30 2022-10-06 苏州开拓药业股份有限公司 一种一步法合成乙内酰硫脲衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2710597A (en) * 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
US5948781A (en) 1997-05-27 1999-09-07 Pfizer Inc Adamantyl substituted oxindoles as pharmaceutical agents
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体

Also Published As

Publication number Publication date
CA2291880A1 (en) 2000-06-02
US6194438B1 (en) 2001-02-27
JP2000186075A (ja) 2000-07-04
EP1006113A1 (en) 2000-06-07

Similar Documents

Publication Publication Date Title
BR9905788A (pt) Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados
BR9913138A (pt) Derivados de quinolin-2-ona substituìdos com alquinila úteis como agentes contra o câncer
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BR0005633A (pt) Derivados de quinolina úteis para inibição da farnesil proteìna transferase
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
BR9912073A (pt) Composições farmacêuticas que compreendem 2-quinolonas
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
PT928788E (pt) Compostos farmaceuticamente activos
BRPI9909282A (pt) compostos de éter aminociclohexílicos e usos dos mesmos.
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
BR0014116A (pt) Uso de um composto, composto, métodos para preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9814340A (pt) Derivados de indol como inibidores de fator xa
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
EP1362846A4 (en) AMINOETHANOL DERIVATIVES
BRPI0408338A (pt) piperidinas substituìdas como novos inibidores de mdm2-p53
BR0314699A (pt) Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula
NO20003018L (no) Triazinangiogenese-inhibitorer
IL148426A0 (en) α-HYDROXY ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BR9916422A (pt) Saponinas antiprotozoárias
ATE238981T1 (de) Antitumorwirkstoffe
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal

Legal Events

Date Code Title Description
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07D 451/02, C07D 401/14, C07D 233/70, C07F 9/6558, A61K 31/4178, A61K 31/4427, A61K 31/4433, A61K 31/4439, A61K 31/444, A61K 31/4545, A61K 31/46, A61K 31/675, A61P 35/00

Ipc: C07D 451/02 (2008.04), C07D 401/14 (2008.04), C07D

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.